학술논문
TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma
Document Type
Article
Author
Morschhauser, Franck; Dahiya, Saurabh; Palomba, M. Lia; Martin Garcia-Sancho, Alejandro; Reguera, Juan Luis; Kuruvilla, John; Jaeger, Ulrich; Cartron, Guillaume; Izutsu, Koji; Dreyling, Martin; Kahl, Brad S.; Ghesquieres, Herve; Ardeshna, Kirit; Goto, Hideki; Barbui, Anna Maria; Abramson, Jeremy S.; Borchmann, Peter; Fleury, Isabelle; Mielke, Stephan; Skarbnik, Alan; de Vos, Sven; Kamdar, Manali; Karmali, Reem; Viardot, Andreas; Farazi, Thalia; Fasan, Omotayo; Lymp, James; Vedal, Min; Nishii, Rina; Avilion, Ariel; Papuga, Jessica; Nastoupil, Loretta J.
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p602-602, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Background: Results with CD19-directed CAR T cell therapy in patients (pts) with second-line (2L) R/R follicular lymphoma (FL) and high-risk features, such as progression of disease within 24 months (POD24) from diagnosis or double refractory to anti-CD20 antibody plus alkylator, have not been previously reported. TRANSCEND FL (NCT04245839), a global, phase 2, open-label, single-arm, multicohort, pivotal study, assessed efficacy and safety of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel) in pts with second line or later (2L+) R/R indolent NHL. Some data from the primary analysis were previously reported, including safety in 2L+ R/R FL, and focused on efficacy in third line or later R/R FL (Morschhauser F, et al. Hematol Oncol2023;41[S2]:877‒880). Here, we report primary analysis results in the cohort of pts with 2L high-risk R/R FL.